ICCM (Icecure Medical) Quality Rank


ICCM Icecure Medical Ltd ICCM
46 GF Score
Price $3.98
GF Value $21.26
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Icecure Medical Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Icecure Medical Quality Rank Related Terms

ICCM
46GF Score
Icecure Medical Ltd ICCM
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Icecure Medical (ICCM) Overvalued in 2026?

Based on GuruFocus' analysis, Icecure Medical stock appears to be undervalued. The current stock price of $3.98 is trading 81.3% below its estimated GF Value™ of $21.26. GuruFocus considers Icecure Medical to be Possible Value Trap.

Key valuation signals for ICCM:

  • Quality Rank:
  • GF Value™: $21.26 vs. price of $3.98 (81.3% below fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the ICCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Icecure Medical Business Description

Address 7 Haeshel Street, PO Box 3163, Caesarea, ISR, 3079504
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
46GF Score

Get the complete analysis for ICCM

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.98
Price
$21.26
GF Value